<- Back to digest

JSES - 2026-05-01 - Journal Article; Comparative Study

Reverse total shoulder arthroplasty demonstrates improved functional outcomes and equivocal midterm survival compared to hemiarthroplasty following oncologic reconstruction in proximal humerus replacement.

Hamad CD, Golzar A, Sridharan M, Kendal J, Brown DE, Trikha R, Sekimura TK, Fice MP, Christ AB, Bernthal NM, Wessel LE

retrospective cohortLOE IIIn = 173 (146 hemiarthroplasty, 27 rTSA)Mean 59.3 months (hemiarthroplasty), 24.9 months (rTSA)

Topics

shoulder elbowsports
PMID: 41177292DOI: 10.1016/j.jse.2025.10.008View on PubMed ->

Key Takeaway

rTSA achieved 109° abduction versus 32° with hemiarthroplasty in oncologic proximal humerus replacement, with equivalent overall implant survival despite shorter time to failure in the rTSA group (2.1 vs. 55.2 months).

Summary Depth

Choose how much analysis to show on this article page.

Summary

This retrospective study compared ROM, implant survivorship, and resection parameters in 173 patients undergoing oncologic proximal humerus replacement with either hemiarthroplasty or rTSA between 1981 and 2024. rTSA demonstrated significantly superior abduction (109° vs. 32°), forward flexion (110° vs. 34°), and external rotation (38° vs. 17°), all P≤.002. Overall Kaplan-Meier survival was equivalent (P=.710), but time to failure was markedly shorter in rTSA (2.1 vs. 55.2 months), and APC reconstruction below the deltoid tuberosity yielded inferior forward flexion (56° vs. 121°, P=.040).

Key Limitation

The rTSA cohort has less than half the mean follow-up of the hemiarthroplasty cohort (24.9 vs. 59.3 months), making equivalent overall survival a premature conclusion and likely underestimating late rTSA failure events.

Original Abstract

BACKGROUND

Oncologic proximal humerus replacement (PHR) poses challenges because of disruption of the rotator cuff and capsule. We evaluated functional outcomes, implant survivorship, resection length, and stem-to-resection length ratio in patients undergoing hemiarthroplasty or reverse total shoulder arthroplasty (rTSA) with either endoprosthesis or allograft-prosthesis composite (APC) reconstruction.

MATERIALS AND METHODS

This is a retrospective cohort study of 173 patients undergoing oncologic PHR between 1981 and 2024 (146 hemiarthroplasties; 27 rTSAs). Mean follow-up was 59.3 ± 81.9 months (hemiarthroplasty) and 24.9 ± 26.6 months (rTSA). Implant failures were classified using the Henderson system. Shoulder range of motion (ROM)-abduction, forward flexion (FF), and external rotation (ER)-was assessed at most recent follow-up. Independent t tests compared ROM between groups. Pearson correlation evaluated relationships between resection length and ROM. Stem-to-resection length ratios were analyzed for impact on implant survival. Kaplan-Meier analysis assessed implant survivorship.

RESULTS

RTSA showed significantly greater ROM than hemiarthroplasty: abduction (109° vs. 32°), FF (110° vs. 34°), ER (38° vs. 17°) (P < .001, P < .001, and P = .002, respectively). In rTSA, abduction, FF, and ER did not correlate with resection length (P = .710, P = .910, and P = .710, respectively), and stem-to-resection length ratio did not predict survival. In resections below the deltoid tuberosity, APC reconstructions had worse FF (56° vs. 121°, P = .040). Time to failure was shorter in rTSA (2.1 vs. 55.2 months, P < .001), although overall survival did not differ (P = .710).

CONCLUSION

RTSA yields superior ROM compared with hemiarthroplasty without compromising implant longevity. APC use below the deltoid tuberosity may reduce functional outcomes. Early rTSA failures warrant improved follow-up and multicenter analysis.